Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies

[1]  Y. Carmeli,et al.  A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  Á. Soriano,et al.  Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. , 2009, The Journal of antimicrobial chemotherapy.

[3]  J. Rodríguez-Baño,et al.  Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. , 2008, The Journal of antimicrobial chemotherapy.

[4]  F. Gudiol,et al.  Prospective Study of Fecal Colonization by Extended-Spectrum-β-Lactamase-Producing Escherichia coli in Neutropenic Patients with Cancer , 2008, Antimicrobial Agents and Chemotherapy.

[5]  A. Oliver,et al.  Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. , 2008, Archives of internal medicine.

[6]  K. Laupland,et al.  Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern , 2008 .

[7]  G. Hedin,et al.  Molecular Epidemiology of Extended-Spectrum β-Lactamases among Escherichia coli Isolates Collected in a Swedish Hospital and Its Associated Health Care Facilities from 2001 to 2006 , 2007, Journal of Clinical Microbiology.

[8]  V. Montori,et al.  Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[9]  K. A. Kamath,et al.  Fecal Carriage of Extended-Spectrum β-Lactamase–Producing Escherichia coli and Klebsiella pneumoniae in Patients and Asymptomatic Healthy Individuals , 2007, Infection Control & Hospital Epidemiology.

[10]  J. Rodríguez-Baño,et al.  Bacteremia Due to Extended-Spectrum β-Lactamase–Producing Escherichia coli in the CTX-M Era: A New Clinical Challenge , 2006 .

[11]  Y. Cho.  Inflow of Extended-Spectum β -Lactamase-Producing Enterobacteriaceae into the Hospital , 2006 .

[12]  D. Paterson,et al.  A change in the epidemiology of infections due to extended-spectrum beta-lactamase-producing organisms. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  J. Ariza,et al.  Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[14]  P. Coll,et al.  Surveillance of extended-spectrum beta-lactamases from clinical samples and faecal carriers in Barcelona, Spain. , 2005, The Journal of antimicrobial chemotherapy.

[15]  F. Baquero,et al.  Dramatic Increase in Prevalence of Fecal Carriage of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae during Nonoutbreak Situations in Spain , 2004, Journal of Clinical Microbiology.

[16]  P. Coll,et al.  Community Transmission of Extended-Spectrum β-Lactamase , 2003, Emerging infectious diseases.

[17]  S. Zinner.  Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  J. Ariza,et al.  Epidemiology and Successful Control of a Large Outbreak Due to Klebsiella pneumoniae Producing ExtendedSpectrum β-Lactamases , 1998, Antimicrobial Agents and Chemotherapy.

[19]  J. Yoo,et al.  Molecular epidemiological analysis of quinolone-resistant Escherichia coli causing bacteremia in neutropenic patients with leukemia in Korea. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  F. Tubau,et al.  Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis , 1996, Antimicrobial agents and chemotherapy.

[21]  D H Persing,et al.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.

[22]  F. Tubau,et al.  Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  W. Breitbart,et al.  Clinical update , 1994, Psycho-oncology.

[24]  D. Hosmer,et al.  Applied Logistic Regression , 1991 .

[25]  F. J. Castillo García,et al.  Prevalence of fecal carriage of ESBL-producing Enterobacteriaceae in hospitalized and ambulatory patients during two non-outbreak periods , 2006, European Journal of Clinical Microbiology & Infectious Diseases.